What is HC Wainwright’s Estimate for Celcuity Q1 Earnings?

Celcuity, Inc. (NASDAQ:CELC) – HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Celcuity in a research note issued to investors on Monday, May 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.05) for the quarter, down from their prior forecast of ($1.04). The consensus estimate for Celcuity’s current full-year earnings is ($3.97) per share. HC Wainwright also issued estimates for Celcuity’s Q2 2026 earnings at ($1.12) EPS, Q3 2026 earnings at ($1.17) EPS, Q4 2026 earnings at ($0.36) EPS, FY2027 earnings at $1.77 EPS, FY2028 earnings at $7.60 EPS, FY2029 earnings at $12.01 EPS and FY2030 earnings at $16.69 EPS.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09.

Several other research firms also recently commented on CELC. Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a report on Monday. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Monday, April 20th. Craig Hallum reaffirmed a “buy” rating and issued a $189.00 price objective on shares of Celcuity in a report on Monday. Finally, Wolfe Research reiterated an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and a consensus target price of $134.50.

Celcuity Trading Down 2.3%

Shares of CELC opened at $141.69 on Wednesday. Celcuity has a fifty-two week low of $9.51 and a fifty-two week high of $151.02. The business has a 50-day moving average of $115.27 and a 200 day moving average of $103.28. The firm has a market cap of $6.85 billion, a P/E ratio of -37.39 and a beta of 0.09. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total value of $330,810.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $745,425.20. This represents a 30.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Creative Planning purchased a new stake in Celcuity in the second quarter valued at approximately $177,000. Rhumbline Advisers increased its holdings in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Celcuity in the 2nd quarter worth $169,000. Quantinno Capital Management LP raised its position in shares of Celcuity by 20.7% during the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after buying an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co raised its position in shares of Celcuity by 285.8% during the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after buying an additional 60,849 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Topline Phase 3 VIKTORIA‑1 results reportedly show gedatolisib improved progression‑free survival vs Novartis’ alpelisib in the PIK3CA‑mutant cohort — a direct efficacy win versus a marketed competitor that materially strengthens commercial prospects. Celcuity’s gedatolisib beats Novartis drug in Phase III test
• Positive Sentiment: Company says it will pursue a supplemental NDA filing for the PIK3CA‑mutant data and will present detailed results at ASCO — this creates a clear near‑term regulatory/visibility catalyst on top of the already accepted NDA for a different subgroup. Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib
• Positive Sentiment: Multiple analysts raised ratings/targets after the news (Needham to $157, Citizens/JMP to $160 and others), which likely amplified buying and gave investors new valuation anchors. Needham & Company LLC Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price
• Neutral Sentiment: Broad media coverage (MarketWatch, FierceBiotech, Yahoo/Finance) is increasing awareness ahead of ASCO and the upcoming PDUFA for the previously accepted NDA, pushing volumes and short‑term attention. Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results
• Neutral Sentiment: Clinical summaries and independent coverage recap VIKTORIA‑1 toplines and planned ASCO presentation; these reports inform but leave detailed subgroup and safety readouts pending (ASCO presentation will be important). Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
• Negative Sentiment: Insider selling has been reported recently (multiple open‑market sales), which some investors view as a cautionary signal despite positive trial news. Insider trading and institutional flow summary
• Negative Sentiment: High valuation and negative reported EPS mean the stock’s rally rests on future commercial execution and regulatory approvals; volatility and downside risk remain if upcoming ASCO or FDA updates disappoint. Valuation note

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.